Gain Therapeutics (GANX) Capital Expenditures (2020 - 2026)
Gain Therapeutics (GANX) posted quarterly Capital Expenditures of $913.0 for Q1 2026, up 198.49% year-over-year from $305.87 in Q1 2025, and up 271.29% quarter-over-quarter from -$533.0 in Q4 2025.
Gain Therapeutics (GANX) Capital Expenditures (2020 - 2026) Analysis & Trends
Gain Therapeutics' Capital Expenditures history runs 7 years deep, the most recent figure standing at $913.0 for Q1 2026.
- In Q1 2026, Capital Expenditures rose 198.49% year-over-year to $913.0; the TTM figure through Mar 2026 stood at -$1012.0 (down 105.93% YoY), while the FY2025 annual figure was -$2852.0, down 113.58% from the prior year.
- Capital Expenditures for Q1 2026 stood at $913.0, up from -$533.0 in the prior quarter.
- The five-year high for Capital Expenditures was $155252.0 in Q4 2022, with the low at -$204727.0 in Q3 2022.
- The 5-year median for Capital Expenditures is $913.0 (2026), against an average of $2195.3.
- Peak annual rise in Capital Expenditures reached 2368.92% in 2024, while the deepest fall reached 2984.21% in 2024.
- Gain Therapeutics' Capital Expenditures stood at $155252.0 in 2022, then tumbled by 99.99% to $19.0 in 2023, then plunged by 2984.21% to -$548.0 in 2024, then advanced by 2.74% to -$533.0 in 2025, then jumped by 271.29% to $913.0 in 2026.
- Business Quant data shows GANX's Capital Expenditures at $913.0 in Q1 2026, -$533.0 in Q4 2025, and -$541.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Gain Therapeutics | 85.97 Mn | 85.97 Mn | - | -10,766.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -10,766.00 |
| Jun 30, 2026 | -10,766.00 |
| Mar 31, 2026 | 913.00 |
| Mar 31, 2026 | 913.00 |
| Dec 31, 2025 | -533.00 |
| Dec 31, 2025 | -533.00 |
| Sep 30, 2025 | -541.00 |
| Sep 30, 2025 | -541.00 |
| Jun 30, 2025 | -851.00 |
| Jun 30, 2025 | -851.00 |
| Mar 31, 2025 | -927.00 |
| Mar 31, 2025 | -927.00 |
| Dec 31, 2024 | -548.00 |
| Dec 31, 2024 | -548.00 |
| Sep 30, 2024 | 16,048.00 |
| Sep 30, 2024 | 16,048.00 |
| Jun 30, 2024 | 2,479.00 |
| Jun 30, 2024 | 2,479.00 |
| Mar 31, 2024 | 3,021.00 |
| Mar 31, 2024 | 3,021.00 |